Get started
Author

Giovanni Zarrilli

Observed name: G. Zarrilli
ORCID: 0009-0008-9253-6326
Observed ORCID: 0009-0008-9253-6326
OpenAlex ID: A5043754978
The Immunopathological and Histological Landscape of COVID-19-Mediated Lung Injury
2021 · Giovanni Zarrilli, Valentina Angerilli, et al. · International Journal of Molecular Sciences · 46
PDF
miRNAs Involved in Esophageal Carcinogenesis and miRNA-Related Therapeutic Perspectives in Esophageal Carcinoma
2021 · Giovanni Zarrilli, Francesca Galuppini, et al. · International Journal of Molecular Sciences · 39
PDF
The Tumor Microenvironment of Primitive and Metastatic Breast Cancer: Implications for Novel Therapeutic Strategies
2020 · Giovanni Zarrilli, Gianluca Businello, et al. · International Journal of Molecular Sciences · 39
PDF
Epigenetics of oral and oropharyngeal cancers (Review)
2018 · Daniela Russo, Francesco Merolla, et al. · Biomedical Reports · 35
PDF
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer
2023 · Federica Miglietta, Moira Ragazzi, et al. · Clinical Cancer Research · 13
PDF
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
2022 · Maria Vittoria Dieci, Luisa Carbognin, et al. · British Journal of Cancer · 10
PDF
Gastric metastases of breast cancer: Histopathological and molecular characterization of a single Institution case series
2022 · Giovanni Zarrilli, Valentina Angerilli, et al. · Pathology - Research and Practice · 5
PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2− BC patients with residual disease after neoadjuvant chemotherapy: a cohort study
2023 · Federica Miglietta, Valentina Carraro, et al. · Journal of Clinical Pathology · 3
PDF
Immunohistochemical and molecular profiling of uveal melanoma: clinicopathological correlations from an Italian cohort
2026 · Francesco Fortarezza, Giovanni Zarrilli, et al. · Pathologica · 2
Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
2022 · Maria Vittoria Dieci, Luisa Carbognin, et al. · British Journal of Cancer · 1
PDF
[Corrigendum] Epigenetics of oral and oropharyngeal cancers (Review)
2020 · Daniela Russo, Francesco Merolla, et al. · Biomedical Reports · 1
PDF
Supplementary Figure 3 from A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer
2025 · Federica Miglietta, Moira Ragazzi, et al.
PDF
Supplementary Table 3 from A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer
2025 · Federica Miglietta, Moira Ragazzi, et al.
PDF
Supplementary Figure 1 from A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer
2025 · Federica Miglietta, Moira Ragazzi, et al.
PDF
Supplementary Table 2 from A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer
2025 · Federica Miglietta, Moira Ragazzi, et al.
Supplementary Table 1 from A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer
2025 · Federica Miglietta, Moira Ragazzi, et al.
PDF
Supplementary Figure 2 from A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer
2025 · Federica Miglietta, Moira Ragazzi, et al.
PDF
1510 Immunohistochemical and Molecular Profiling of Uveal Melanoma: Insights from a Mono-Institutional Study
2025 · Francesco Fortarezza, Giovanni Zarrilli, et al. · Laboratory Investigation
PDF
Supplementary Table 2 from A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer
2024 · Federica Miglietta, Moira Ragazzi, et al.
Supplementary Table 3 from A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer
2024 · Federica Miglietta, Moira Ragazzi, et al.
Supplementary Table 1 from A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer
2024 · Federica Miglietta, Moira Ragazzi, et al.
Supplementary Figure 2 from A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer
2024 · Federica Miglietta, Moira Ragazzi, et al.
Supplementary Table 3 from A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer
2024 · Federica Miglietta, Moira Ragazzi, et al.
Supplementary Table 2 from A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer
2024 · Federica Miglietta, Moira Ragazzi, et al.
Supplementary Figure 1 from A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer
2024 · Federica Miglietta, Moira Ragazzi, et al.
Works count: 52
Citation count: 194
H-index: 6
I10-index: 6
Year
Topic
Type